Courier Capital LLC Has $1.13 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Courier Capital LLC increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 173.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 154,266 shares of the biopharmaceutical company's stock after purchasing an additional 97,828 shares during the period. Courier Capital LLC owned 0.10% of Ocular Therapeutix worth $1,131,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Point72 Asset Management L.P. lifted its stake in shares of Ocular Therapeutix by 43.9% during the 4th quarter. Point72 Asset Management L.P. now owns 2,935,924 shares of the biopharmaceutical company's stock worth $25,073,000 after purchasing an additional 895,304 shares during the last quarter. Millennium Management LLC acquired a new stake in Ocular Therapeutix during the fourth quarter worth about $3,819,000. Artisan Partners Limited Partnership grew its holdings in Ocular Therapeutix by 26.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company's stock worth $11,398,000 after acquiring an additional 278,610 shares during the period. Rosalind Advisors Inc. grew its holdings in Ocular Therapeutix by 27.5% during the fourth quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company's stock worth $9,639,000 after acquiring an additional 243,700 shares during the period. Finally, Patient Square Capital LP grew its holdings in Ocular Therapeutix by 100.0% in the fourth quarter. Patient Square Capital LP now owns 470,919 shares of the biopharmaceutical company's stock valued at $4,022,000 after purchasing an additional 235,421 shares during the period. 59.21% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, Director Richard L. Md Lindstrom bought 10,000 shares of the stock in a transaction that occurred on Thursday, May 8th. The shares were acquired at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the purchase, the director now directly owns 172,704 shares in the company, valued at $1,202,019.84. The trade was a 6.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Pravin Dugel sold 21,219 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the sale, the insider now directly owns 3,499,099 shares of the company's stock, valued at approximately $25,123,530.82. This represents a 0.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,079 shares of company stock valued at $208,739 in the last quarter. Company insiders own 2.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on OCUL shares. Royal Bank of Canada started coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price objective on the stock. William Blair assumed coverage on Ocular Therapeutix in a research report on Tuesday, April 8th. They set an "outperform" rating for the company. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Thursday, May 29th. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research note on Tuesday, March 4th. Finally, Needham & Company LLC dropped their target price on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $16.25.

Ocular Therapeutix Trading Down 2.5%

NASDAQ OCUL traded down $0.22 on Friday, hitting $8.73. 1,103,822 shares of the stock were exchanged, compared to its average volume of 1,459,896. Ocular Therapeutix, Inc. has a 52-week low of $5.11 and a 52-week high of $11.78. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -6.61 and a beta of 1.42. The company's 50-day moving average price is $7.70 and its two-hundred day moving average price is $7.89.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.